Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...
WALTHAM, MASSACHUSETTS / ACCESS Newswire / February 4, 2025 / Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at ...
WALTHAM, MASSACHUSETTS / ACCESS Newswire / February 4, 2025 / Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI to ...
Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.9% year on year to $17.76 billion. On the other hand, the company ...
US futures were steady as traders weighed the economic implications of tariffs while parsing the latest batch of company ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...
NEW YORK, February 04, 2025 -- ( BUSINESS WIRE )--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and ...
Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback